BIODESIX, INC.
Moat Score — Biodesix, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Biodesix holds 60 issued U.S. and 84 issued foreign patents plus proprietary bioinformatics/algorithm know-how (e.g., VeriStrat's MALDI-ToF classifier), and several tests carry CMS ADLT status backed by peer-reviewed clinical validation. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Two CLIA labs give some processing scale, but the company is smaller than genomics peers like Guardant Health and lacks a structural low-cost position. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | ADLT designation lets several tests be reimbursed near private-payer median rates, a real near-term pricing advantage, but Medicare rate resets and payer negotiations cap long-term pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Diagnostic testing volume does not create network effects between physicians or patients. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Ordering physicians who build workflow trust in Nodify/GeneStrat results have some inertia to switch, and payer coverage decisions add friction, but tests are not deeply embedded systems with high switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The lung-diagnostics niche has room for multiple players; larger competitors like Guardant Health and Tempus AI can and are expanding into adjacent lung testing, limiting any efficient-scale protection. |